TiumBio Co., Ltd. (321550)

Overview

TiumBio Co., Ltd. is a pioneering drug discovery company dedicated to the research and development of innovative therapeutics for patients suffering from rare diseases that lack adequate treatment options. Founded in the year 2016 and situated in Seongnam-si, South Korea, the company leverages cutting-edge science and strategic partnerships to address the unmet needs of patients around the globe. Through its collaboration with Oncodesign Société Anonyme, TiumBio is expanding its efforts in the development of fibrosis drug candidates, showcasing its commitment to tackling some of the most challenging medical conditions.

Products and Services

• NCE401

  This is one of the flagship chemical entity-based drugs under development by TiumBio. It is designed to target specific pathways involved in certain rare diseases, representing the company’s innovative approach to drug discovery.

• NCE403

  Another key chemical entity-based drug, NCE403 is in the pipeline for addressing specific unmet medical needs in the realm of rare diseases, underscoring TiumBio's dedication to providing targeted therapeutic solutions.

• NCE406

  NCE406 is part of TiumBio’s array of chemical entity-based drugs aimed at treating rare diseases. Its development is a testament to the company’s focus on advancing healthcare outcomes for patients facing limited treatment options.

• NCE604

  As part of the company's expanded focus, NCE604 represents a new direction in biopharmaceuticals being explored by TiumBio, aiming to leverage biological pathways for the treatment of rare disease conditions.

• NCE611

  This addition to TiumBio’s product pipeline signifies the company’s ongoing efforts to explore and develop biopharmaceuticals. NCE611 is designed with the intent to offer innovative treatment options for patients with rare diseases, based on cutting-edge biotechnological research.

• NBP

  NBP stands as a pivotal project in TiumBio's endeavors into biopharmaceuticals, representing a significant advancement in the company's mission to develop drugs that can deliver life-changing treatments to patients suffering from rare diseases with previously unaddressed medical needs.